PATRYS LIMITED — Investor Relations & Filings

Patrys Limited is a biotechnology company focused on the development of novel antibody-based therapies for the treatment of cancer. The company's primary platform is based on Deoxymabs, a suite of antibodies derived from the 3E10 lupus autoantibody. These antibodies possess the unique capability to cross cell membranes and the blood-brain barrier, targeting the cell nucleus to inhibit DNA damage repair mechanisms. Patrys' lead candidates, PAT-DX1 and PAT-DX3, are engineered to exploit the DNA repair deficiencies inherent in many cancer cells, particularly aggressive forms such as glioblastoma and triple-negative breast cancer. Beyond direct anti-tumor activity, the Deoxymab platform is designed for use in synthetic lethality applications and as a delivery vehicle for therapeutic payloads, including nanoparticles and imaging agents, to target primary and metastatic tumors.